Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07291232
PHASE1
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Sponsor: AbbVie
View on ClinicalTrials.gov
Summary
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
Official title: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Subcutaneous Doses of ABBV-295 in Adult Subjects With Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2025-11-19
Completion Date
2026-10
Last Updated
2025-12-18
Healthy Volunteers
No
Conditions
Interventions
DRUG
ABBV-295
Subcutaneous Injections
DRUG
Placebo
Subcutaneous Injections
Locations (1)
Acpru /Id# 278624
Grayslake, Illinois, United States